文献速递乳腺癌

免疫细胞表达糖皮质激素受体的三阴性乳腺癌预后更好

Triple-negative breast cancers with expression of glucocorticoid receptor in immune cells show better prognosis.
PubMed 文献 · Ann Oncol · 2021-05-01

该研究通过免疫组化检测175例浸润性乳腺癌肿瘤细胞、基质细胞和肿瘤浸润淋巴细胞(TIL)中糖皮质激素受体(GR)的表达,分析无病生存。结果显示GR阳性肿瘤总生存显著优于阴性(平均生存85 vs 59个月,p=0.04);TNBC中免疫细胞GR高表达者生存更好(74 vs 41个月,p=0.03),且GR阴性TNBC淋巴结转移更多(p=0.04)。

要点

  • TNBC中免疫细胞GR表达与更好生存相关,与模型系统中免疫抑制作用的报道相反。
  • GR阳性乳腺癌总体生存显著优于GR阴性(平均85 vs 59个月,p=0.04)。
  • GR阴性TNBC淋巴结转移率更高(p=0.04),其他临床特征无差异。

核心结论

  • 乳腺癌GR表达与更好预后相关,TNBC中免疫细胞GR表达亦与更好生存相关。

研究设计与样本

  • 回顾性研究,对175例浸润性乳腺癌肿瘤标本进行GR免疫组化检测并长期随访。
  • GR分别在浸润性肿瘤细胞、基质细胞和肿瘤浸润淋巴细胞中评估,>1%细胞染色为阳性。

主要发现

  • 175例中ER阳性121例(70%),ER阴性53例(30%),三阴性51例(29%)。
  • 130/175(74%)肿瘤细胞GR阳性,147/175(84%)TIL中GR阳性。
  • ER阳性与ER阴性肿瘤GR分布无显著差异(78% vs 66%,p=0.1)。
  • TNBC中肿瘤细胞GR阳性28/51(54%),TIL中GR阳性36/51(70%)。
  • GR阳性肿瘤平均生存85个月 vs GR阴性59个月(p=0.04);TNBC中免疫细胞GR高表达平均生存74 vs 41个月(log rank p=0.03)。

临床怎么用

  • 化疗期间常用糖皮质激素缓解症状,GR状态检测可能对TNBC预后判断有参考价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glucocorticoid receptor (GR) is shown to have variable frequency of expression in invasive tumors of the breast. Investigation of additional nuclear receptors like GR in receptor negative tumors like triple negative breast cancer (TNBC) may have prognostic and therapeutic significance. METHODS: Expression of GR was evaluated by immunohistochemistry in 175 tumors of invasive breast cancer with long term follow up. GR Expression was separately evaluated in invasive tumor cells, stromal cells and tumor infiltrating lymphocytes (TIL's). Staining pattern was categorised as positive when more than 1% of the cells stained in each subpopulation of cells. Disease free survival was analysed between GR positive and negative status by Kaplan Meier analysis. RESULTS: Of the 175 tumors, 121 (70%) were ER positive, 53 (30%) were ER negative and 29% (51) were triple negative. 74% (130/175) tumors showed expression of GR in invasive tumor cells while (84%) 147/175 had expression in TIL's. No significant difference in distribution of GR was noted between ER positive and ER negative tumors (78% vs 66%, p-0.1). Of the TNBC's 54% (28/51) and 70% (36/51) showed expression of GR in invasive tumor and TIL's respectively. Overall, GR positive tumors had significant better survival than GR negative tumors (mean survival time of 85 vs 59 months respectively, p-0.04) Contrary to the reports that GR expression in TIL's are associated with immunosuppressive activity in model systems, TNBC's with increased expression of GR in immune cells were associated with better survival (Mean survival time 74 vs 41 months, log rank test- p-0.03). TNBC tumors which were GR negative had higher lymph node metastases (p-0.04) and none of the other clinical features like age, menopausal state, tumor size and grade were different between GR positive and negative tumors within TNBC. CONCLUSIONS: Glucocorticoids (GC) are often used to alleviate the adverse symptoms during chemotherapy. Determining the GR status is of importance due to the pro cell survival effect of the glucocorticoids mediated through GR during chemotherapy. Though GC mediated effects on chemotherapy are controversial, our results indicate favourable effects in TNBC.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Prabhu JS, Patil S, Rajarajan S, et al. Triple-negative breast cancers with expression of glucocorticoid receptor in immune cells show better prognosis. Ann Oncol. 2021. PMID: 34220400. doi:10.1016/j.annonc.2021.03.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。